Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review
Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).
1 finding from 1 review
Intervention not reported
Weight: Gain‐more than or equal to 7% from baseline · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
The intervention showed no clear difference in weight: Gain‐more than or equal to 7% from baseline (moderate certainty).
1 finding from 1 review
Intervention not reported
Weight: BMI not improved · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Physiological measure: Metabolic syndrome · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Global state: Average change (CGI‐I, high=good) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Mental state: Average change (PANSS, high decline=good) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Weight: BMI not improved · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Intervention not reported
Adverse events: Any event · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
The intervention showed no clear difference in adverse events: Any event (moderate certainty).
1 finding from 1 review
Intervention not reported
Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether the intervention changes satisfaction with care: Loss to (very low certainty).
1 finding from 1 review
Physiological measure: Metabolic syndrome · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Global state: Changing dose because of deterioration ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Changing dose because of deterioration ‐ switching to… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Mental state: Deteriorated ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in mental state: Deteriorated ‐ switching to haloperidol decanoate from… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Adverse effects: serious · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (very low certainty).
1 finding from 1 review
Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
2 findings from 1 review
Global outcome: Number of additional injections ‐ 2‐4 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 2‐4 injections compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Global outcome: Number of additional injections ‐ 5 or more · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 5 or more compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ cardiovascular ‐ hypotension compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects ‐ important extrapyramidal adverse effects · patients with psychosis‐induced aggression or agitation
1 finding from 1 review